Dr. Robert Kyle is a multiple myeloma key opinion leader, physician, researcher, and professor at the Mayo Clinic. Dr. Kyle has dedicated his life to caring for multiple myeloma patients and studying the disease.

His work in myeloma began with his residency at the Mayo Clinic in the late 1950s, where he measured monoclonal protein levels in more than 6,500 myeloma and non-myeloma patients to identify a spike characteristic of multiple myeloma. He has authored more than 850 research papers…

People with high-risk, smoldering multiple myeloma who are treated with Revlimid (lenalidomide) and dexamethasone (Decadron) take longer to progress to full-blown multiple myeloma than their counterparts, according to interim results of an ongoing Phase 3 study. Researchers presented the findings at the American Society of Hematology’s (ASH) 51st Annual Meeting.

“For the first time, we are seeing a study which is addressing the question of the early treatment of patients with smoldering myeloma,” said Dr. Brian Durie, a…

Results from recent Phase 1/2 clinical trials show that a perifosine, Velcade (bortezomib) and dexamethasone (Decadron) combination treatment is safe and effective for relapsed and refractory multiple myeloma. Perifosine is an alkyl-phosphocholine compound that controls cell division, cell growth and cell death, and is currently investigated for the treatment of multiple myeloma. Researchers presented their findings on December 5 at the American Society of Hematology’s 51^st Annual Meeting.

“Great meeting—lots of exciting new developments for multiple…

Elderly people with multiple myeloma have better treatment options now than ten years ago. In the past decade, the introduction of thalidomide (Thalomid), Velcade (bortezomib), and Revlimid (lenalidomide) have improved patients’ response to treatment and increased survival time, even when used without stem cell transplants.

In the July issue of Current Opinion in Hematology, Dr. Donna E. Reece, a physician and researcher at the Princess Margaret Hospital in Toronto, reviewed the current approaches to treating newly diagnosed…

The 51st annual meeting of the American Society of Hematology (ASH) kicks off in two weeks in New Orleans. The meeting will feature presentations on the latest in peer-reviewed multiple myeloma research, December 5 through December 8.

ASH annual meetings keep hematologists up to date on research and treatment advances from the past year. According to ASH, the meeting has “a superb educational program,” “cutting-edge scientific sessions,” and presentations that “contain the latest and most exciting developments in scientific research.”…